Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 181, Issue 1-2, 2006, Pages 29-33

  Tüzün, Erdem ^a   Saini, Shamsher S ^a   Morgan, B Paul ^b   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Autoimmunity; CD59; Complement; Experimental autoimmune myasthenia gravis; Myasthenia gravis

Indexed keywords

CD59 ANTIGEN; CHOLINERGIC RECEPTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; INTERLEUKIN 2; MEMBRANE PROTEIN;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNIZATION; KNOCKOUT MOUSE; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANIMALS; ANTIGENS, CD59; B-LYMPHOCYTES; CELL DIVISION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISEASE SUSCEPTIBILITY; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PROTEIN SUBUNITS; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES; TORPEDO;

EID: 37849188628     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.07.016     Document Type: Article

References (20)

1. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140 (1988) 2589-2592
2. Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N., Xu Y., and Medof M.E. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201 (2005) 1523-1530
3. Holt D.S., Botto M., Bygrave A.E., Hanna S.M., Walport M.J., and Morgan B.P. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98 (2001) 442-449
4. Kaminski H.J., Li Z., Richmonds C., Lin F., and Medof M.E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 189 (2004) 333-342
5. Korty P.E., Brando C., and Shevach E.M. CD59 functions as a signal-transducing molecule for human T cell activation. J. Immunol. 146 (1991) 4092-4098
6. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., and Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 110 (2002) 1269-1274
7. Longhi M.P., Sivasankar B., Omidvar N., Morgan B.P., and Gallimore A. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. J. Immunol. 175 (2005) 7098-7102
8. Mead R.J., Neal J.W., Griffiths M.R., Linington C., Botto M., Lassmann H., and Morgan B.P. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab. Invest. 84 (2004) 21-28
9. Meinl E., Klinkert W.E., and Wekerle H. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am. J. Pathol. 139 (1991) 995-1008
10. Morgan B.P., and Harris C.L. Complement regulatory proteins (1999), Academic Press, London, UK 155-166
11. Morgan B.P., van den Berg C.W., Davies E.V., Hallett M.B., and Horejsi V. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur. J. Immunol. 23 (1993) 2841-2850
12. Pizzo P., Giurisato E., Tassi M., Benedetti A., Pozzan T., and Viola A. Lipid rafts and T cell receptor signaling: a critical re-evaluation. Eur. J. Immunol. 32 (2002) 3082-3091
13. Saoudi A., Bernard I., Hoedemaekers A., Cautain B., Martinez K., Druet P., De Baets M., and Guery J.C. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J. Immunol. 162 (1999) 7189-7197
14. Turnberg D., Botto M., Warren J., Morgan B.P., Walport M.J., and Cook H.T. CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J. Am. Soc. Nephrol. 14 (2003) 2271-2279
15. Tuzun E., Meriggioli M.N., Rowin J., Yang H., and Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J. Autoimmun. 24 (2005) 261-268
16. Tuzun E., Scott B.G., Goluszko E., Higgs S., and Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171 (2003) 3847-3854
17. Tuzun E., Scott B.G., Yang H., Wu B., Goluszko E., Guigneaux M., Higgs S., and Christadoss P. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J. Immunol. 172 (2004) 5743-5752
18. Tuzun E., Saini S.S., Yang H., Alagappan D., Higgs S., and Christadoss P. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 174 (2006) 157-167
19. Williams A.S., Mizuno M., Richards P.J., Holt D.S., and Morgan B.P. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum. 50 (2004) 3035-3044
20. Wu B., Goluszko E., and Christadoss P. In: Coligan M.J., Kruisbeek A.M., Margulies D.H., Shevach E.M., and Strober W. (Eds). Experimental autoimmune myasthenia gravis in the mouse. Current Protocols of Immunology vol. 3:8.1 (1997), John Wiley & Sons, New York, USA 1-16